Escalon(R) Announces FDA 510(K) Clearance for D3 Hematol...( WAYNE Pa. Dec. 18 /- Escalon Medi...),Health

WAYNE, Pa., Dec. 18 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq Capital Market: ESMC) today announced that its Drew Scientific subsidiary received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the D3 Hematology System, an automatic three-part differential Hematology Analyzer. Drew Scientific plans to commence shipments of the product in the United States by month-end.

"The FDA clearance represents a major step for Drew, as it now provides two upgraded instruments for sale in fiscal 2008 along with the TRILOGY Analyzer that was approved in July," said Frank Matuszak, Drew's Vice President of Sales and Marketing. "For the past twelve months, we have successfully distributed the D3 System outside of the United States. We expect that the D3 will be equally well received in the U.S. marketplace."

The D3 Hematology System adds to the Company's wide range of top quality and leading edge hematology systems. This flexible and easy-to-use instrument offers simple installation, low maintenance and immediate user acceptance and productivity. The D3 incorporates advanced technology for superior reliability of 3-part differential blood analysis. Features include:
-- Low reagent consumption and very small sample size to minimize

laboratory waste.

-- Advanced user flexibility with easy-to-use built-in color touch screen,

providing on screen histograms and storage of up to 500 records and QC

statistics.

-- Easy installation and user interface with multi-language capability.

For additional information on the D3 Hematology System, please visit the Drew Scientific web site at http://www.drew-scientific.com.

Doug Nickols, President of Drew Scientific, commented, "FDA clearance is another important step in the continued development of the D3 Hematology System. With this advancement and continued growing i
'/>"/>